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BACKGROUND: Standalone interspinous process devices (IPDs) to treat degenerative
lumbar spinal stenosis with neurogenic intermittent claudication (NIC) have shown
ambiguous results in the literature.
OBJECTIVE: To show that a minimally invasive percutaneous IPD is safe and noninferior
to standalone decompressive surgery (SDS) for patients with degenerative lumbar spinal
stenosis with NIC.
METHODS: A multicenter, international, randomized, controlled trial (RCT) was con-
ducted. One hundred sixty-three patients, enrolled at 19 sites, were randomized 1:1 to
treatment with IPD or SDS and were followed for 24 mo.
RESULTS: There was significant improvement in Zurich Claudication Questionnaire
physical function, as mean percentage change from baseline, for both the IPD and the
SDS groups at 12 mo (primary endpoint) and 24 mo (−32.3 ± 32.1, −37.5 ± 22.8; and −37.9
± 21.7%, −35.2 ± 22.8, both P < .001). IPD treatment was not significantly noninferior
(margin: 10%) to SDS treatment at 12mo (P= .172) butwas significantly noninferior at 24mo
(P = .005). Symptom severity, patient satisfaction, visual analog scale leg pain, and SF-36
improved in both groups over time. IPD showed lowermean surgical time andmeanblood
loss (24 ± 11 min and 6 ± 11 mL) compared to SDS (70 ± 39 min and 189 ± 148 mL, both
P < .001). Reoperations at index level occurred in 18.2% of the patients in the IPD group
and in 9.3% in the SDS group.
CONCLUSION: Confirming 3 recent RCTs, we could show that IPD as well as open decom-
pression achieve similar results in relieving symptoms of NIC in highly selected patients.
However, despite some advantages in secondary outcomes, a higher reoperation rate for
IPD is confirmed.
KEYWORDS: Interspinousdevice,Opendecompression surgery, Lumbar spinal stenosis, Randomized controlled
trial, Neurogenic intermittent claudication, Degenerative lumbar disease
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T he use of interspinous process devices(IPDs) to treat degenerative lumbar spinalstenosis (DLSS) has gone through the
usual cycle of most new medical products before
solid evidence for their use became available:
initial overusage being combined with broad
ABBREVIATIONS: DLSS, degenerative lumbar
spinal stenosis; IPD, interspinous process device;
NIC, neurogenic intermittent claudication; SAE,
serious adverse event; SDS, standalone decom-
pressive surgery; SF-36 v2, Short Form Generated
Health Survey version 2; VAS, visual analog scale;
ZCQ, Zurich Claudication Questionnaire
indications for implantation. In addition, most
surgeons have not taken into account that the
basic design of IPDs differs with respect to
their 2 main indications.1 Some IPDs or inter-
laminar devices are designed as an adjunct to
decompression for “soft” stabilization of minor
degenerative instabilities with lumbar stenosis,
ie, a replacement for pedicle screws.2 Other
IPDs, such as the one in this trial, are designed
as standalone devices to replace open decom-
pression surgery of the spinal canal. They act as a
delordosing implant for indirect decompression,
mimicking the way patients relieve symptoms by
bending over. Level 1 evidence exists with regard
to their superiority over conservative treatment.3
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For the reasons above, the use of IPD has now reached the stage of
overwhelming rejection among spine surgeons. This overlooks the
possibility of a small window of indication for standalone devices.
Recently, the results of 3 randomized clinical trials, overlapping
with the recruitment period for the current study, have been
published.4-6 All studies have shown that IPDs are as effective as
open decompression in treating neurogenic intermittent claudi-
cation (NIC), but with up to 3-fold higher reoperation rates in
the IPD cohorts due mainly to “lack of success.”
The objective of the current study was to show that a minimally
invasive percutaneous IPD is safe and noninferior to standalone
decompressive surgery (SDS) with regards to clinical outcomes in
patients suffering from DLSS with NIC relieved by flexion.
METHODS
Study Design
The NICE study was a prospective 2-yr, multicenter, international,
open label, randomized, controlled, comparative clinical trial designed
and conducted in compliance with ISO 14155:2011 and the Decla-
ration of Helsinki. All patients were suffering from DLSS with NIC
relieved by flexion. Patients were randomized to treatment with either the
minimally invasive percutaneous Aperius PercLID (Medtronic, Dublin,
Ireland) system (IPD) or to SDS, the current standard of care. Patients
were evaluated at baseline, 14 d, 6 wk, and 6, 12, and 24 mo.
Ethics Approval
The protocol was reviewed and approved by the medical ethics
committees of all participating hospitals. Written informed consent was
obtained from all participating patients. This study is registered at Clini-
calTrials.gov (NCT00905359), and the authors confirm that all ongoing
and related trials for this drug/intervention are registered.
Participants
Patients had to provide written informed consent and have at least
6 wk of intermittent NIC due to DLSS at 1 or 2 levels, with symptoms
relieved by flexion. DLSS was confirmed bymagnetic resonance imaging,
and absence of instability by lumbar flexion/extension x-rays. In addition,
the visual analog scale (VAS) leg pain score had to be greater or equal to
back pain. The following exclusion criteria were applied: previous lumbar
surgery, unremitting pain in any spinal position, candidates for instru-
mented decompressive surgery, back pain without leg pain, degenerative
spondylolisthesis > grade 1, spondylolysis, spinous process fracture at
any lumbar level, history of osteoporosis, fragility fracture(s), ankylosis
at the affected level, fixed motor deficit, symptomatic spinal stenosis at
L5-S1 level, symptomatic disc herniation causing radiculopathy at any
level between T12-S1, BMI equal to or higher than 40, scoliosis with
Cobb angle ≥ 25◦, or other spinal deformities.
Eligible patients were randomized to treatment with either IPD (inves-
tigational group) or to SDS (control group). Randomization was imple-
mented by the electronic data capture system, with patients allocated to
either of the 2 treatment groups via blinded blocks in a 1:1 ratio. There
were to be at least 51 analyzable patients per arm (102 in total).
The study was conducted in 19 centers across 10 countries (Australia,
Belgium, France, Germany, Iceland, Italy, Poland, Singapore, Sweden,
and the United Kingdom).
Interventions
Patients randomized to the IPD groupwere operated in prone position
under general or local anesthesia; no bony decompression was performed
in these patients. Under radiographic identification, an incision of
approximately 1.5 cm was made, 6 to 10 cm lateral to the midline. Under
fluoroscopy, the smallest (8 mm) sharp trocar is introduced and advanced
toward the interspinous space, followed by percutaneous insertion of
blunt trocars of increasing size. An inserter is then used to achieve correct
placement of the implant and actuating deploys wings, which expand
on each side of the spinous process, stabilizing the IPD on the midline
and working with the intact supraspinous ligaments to keep the IPD in
place.7 Patients in the SDS group were also operated in prone position
and decompressed with standard microsurgical procedures according to
local practice, ie, laminectomies, bilateral laminotomies, and lamino-
tomies with undercutting.
Outcomes and Assessments
The prespecified primary endpoint was the mean percentage change
in physical function from baseline to 1-yr follow-up, obtained by
the Zurich Claudication Questionnaire (ZCQ), a patient-reported
outcome8. Secondary endpoints evaluated the mean percentage change
from baseline in ZCQ for other assessed timepoints.
Additional secondary endpoints evaluated symptom severity and
patient satisfaction using the ZCQ8 leg pain using VAS scores and quality
of life using the Short Form Generated Health Survey version 2 (SF-
36 v2) questionnaire. The SF-36 v2 questionnaire profiles physical and
mental health in 8 different dimensions, including physical functioning,
role physical, bodily pain, general health, vitality, social functioning, role
emotional, and mental health, each of which is analyzed separately and
combined as a physical component summary and mental component
summary. Finally, the percentage of patients requiring additional surgical
intervention at the index level in the follow-up period was determined,
as well as the proportion of patients with serious adverse events (SAEs).
Changes in physical examination data, walking condition and distance,
use of pain medication, and adverse events were also assessed.
Sample Size Estimation
A sample size calculation was performed to determine the number of
patients needed to detect a noninferior difference of 10% in the primary
endpoint with 80% power, and a one-sided alpha of 5%, comparing
SDS to the IPD. Initially, a standard deviation of 30% on the primary
endpoint was assumed. After finding a pooled standard deviation of 17%
when 71 patients had evaluable data, it was calculated, using a Student
t-test with expected difference of 0.0 and common standard deviation
of 20%, that at least 51 analyzable patients per arm (102 in total) were
needed to show noninferiority with 80% power under the given assump-
tions.
Statistical Methods
The primary objective was to show noninferiority of treatment with
IPD compared to SDS regarding physical function. The noninferiority
margin was defined as 10%. A t-test was performed applying multiple
imputations to replace missing values based on the following variables
(applied in a proc MI model): previous measurements of the same
variable, the baseline value, gender, age, completion status, center, and
treatment group. This approach was used to analyze both primary and
secondary endpoints. There was no correction for multiple testing. It
was prespecified that the intention-to-treat population, consisting of all
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FIGURE 1. Flowchart of patient disposition.
randomized patients who were operated and had at least 1 postoper-
ative assessment, would be used for efficacy analysis. However, the results
reported here are for the per-protocol set. This is a subset of patients
in the intention-to-treat population who were treated according to the
protocol specifications. For this per-protocol subset, patients on whom
surgical procedure as defined per randomization was not performed were
removed.
Time to additional surgical intervention at index level was analyzed
by a Kaplan–Meier analysis and a log-rank test to assess the difference
between both treatment groups. Data were analyzed using SAS/STAT R©
software version 9.3 (SAS Institute Inc, Cary, North Carolina).
RESULTS
Patient Disposition
A total of 215 patients from 19 sites were screened and
consented to inclusion in the study. Of these, 163 patients were
randomized, from January 2010 to April 2014, to the IPD (82) or
SDS (81) group (Figure 1), with 79 patients implanted with the
IPD and 76 patients receiving SDS. Twelve patients (9 IPD and
3 SDS) were lost to follow-up after 12 mo, 2 patients withdrew
consent (1 patient in each group), and 1 IPD patient died, which
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TABLE 1. Baseline Characteristics
IPD SDS P-value
Age (years), mean (range) 65 (26-90) 65 (32-83) .58
Gender (%) 53 49 .75
BMI, mean (range) 29 (22-35) 28 (20-35) .91
Duration of leg symptoms (years), mean (range) 2.6 (0.2-31) 2.5 (0.2-31) .61
ZCQ, physical function (SD) 2.6 (0.6) 2.7 (0.6) .49
ZCQ, symptom severity (SD) 3.3 (0.5) 3.3 (0.5) .48
SF36 v2, PCS, mean (SD) 30.7 (8.1) 30.8 (6.5) .08
SF36 v2, MCS, mean (SD) 44.0 (14.2) 43.4 (15.6) .45
Leg pain (VAS), mean (SD) 7.9 (1.3) 8.0 (1.3) .99
Abbreviations: BMI, body mass index; MCS, mental component summary; PCS, physical component summary; SDS, standalone decompressive surgery; IPD, interspinous process
device; VAS, visual analog scale; ZCQ, Zurich Claudication Questionnaire.
TABLE 2. Procedural Data
IPD SDS P-value
Operating time (minutes), mean (SD) 23.5 (11.2) 69.9 (38.7) <.001
1 level operating time, mean (SD) 19.8 (9.8) 62.0 (35.8) <.001
2 level operating time, mean (SD) 27.9 (11.2) 80.4 (40.9) <.001
Total blood loss (mL), mean (SD) 6.0 (10.8) 188.6 (147.9) <.001
1 level blood loss, mean (SD) 4.4 (4.8) 133.5 (79.1) <.001
2 level blood loss, mean (SD) 8.3 (15.7) 259.1 (183.6) <.001
Abbreviations: SDS, standalone decompressive surgery; IPD, interspinous process device.
resulted in a follow-up rate of 83% and 89% per study group,
respectively. Between 12 and 24 mo, 14 patients (7 IPD and 7
SDS) were lost to follow-up, 1 IPD patient withdrew consent,
and 1 IPD patient died, which resulted in a follow-up rate of 71%
and 81% at 24 mo, respectively. The per-protocol set, used for
reporting efficacy results, was made up of 72 IPD patients and 73
SDS patients.
Baseline Characteristics
Baseline characteristics were similar in both treatment arms
and showed no statistically significant difference (Table 1). Mean
age of included patients was 65 ± 11 (range 26-90) yr. Fifty-one
percent of patients were female. Mean leg pain was 7.9 ± 1.3 and
8.0 ± 1.3 in the IPD and SDS groups, respectively. Mean back
pain was 4.0 ± 2.3 and 4.4 ± 2.0, respectively.
Surgical Treatment
Mean operation time and mean blood loss in the IPD group
(24± 11 min and 6± 11 mL) were significantly lower compared
to the SDS group (70 ± 39 min and 189 ± 148 mL, both P <
.001; Table 2).
Patient-Reported Outcomes
There was a significant improvement in the mean percentage
change from baseline in ZCQ physical function for both the IPD
and the SDS treatment groups at 12 mo (−32.3 ± 32.1, P <
.001 and −37.5 ± 22.8, P < .001, respectively). Comparison of
difference in physical function of the ZCQ between IPD and SDS
groups at baseline and 12-mo follow-up showed a mean inter-
group difference of 5% with a confidence interval of −4 to +15
(P = .172, Figure 2). Therefore, noninferiority of IPD to SDS
treatment, with a 10% acceptable difference margin, could not
be established with statistical significance.
Improvement in ZCQ physical function, predefined as a
decrease of ≥0.5 compared to baseline, was achieved by 62.5%
of the patients of the IPD group and 65.8% of the patients in the
SDS group at 12 mo.
Secondary Outcomes
The improvement in ZCQ physical function remained up to
24 mo for both the IPD and the SDS treatment groups (–37.9
± 21.7%, P < .001 and –35.2 ± 22.8, P < 0.001). Comparison
of difference in ZCQ physical function between IPD and SDS
treatment groups at baseline and 24 mo showed noninferiority of
IPD treatment compared with SDS treatment (mean intergroup
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TABLE 3. ZCQ at Baseline and 12- and 24-mo Follow-up
Baseline 12 mo %CfB (SD) 24mo %CfB (SD) P-value
Physical function
IPD, mean (SD) 2.6 (0.6) 1.7 (0.7) −32.3 (32.1) 1.5 (0.5) –37.9 (21.7) <.001
SDS, mean (SD) 2.7 (0.6) 1.6 (0.6) −37.5 (22.8) 1.7 (0.6) –35.2 (22.8) <.001
Symptom severity
IPD, mean (SD) 3.3 (0.5) 2.2 (0.8) −31.2 (26.9) 1.9 (0.7) –40.3(21.9) <.001
SDS, mean (SD) 3.3 (0.5) 2.1 (0.8) −36.4 (24.5) 2.1 (0.7) –32.8 (23.9) <.001
Abbreviations: CfB, change from baseline; SDS, standalone decompressive surgery; IPD, interspinous process device.
FIGURE 2. Mean physical function score according to Zurich Claudication
Questionnaire at all follow-up time points. Intergroup comparison showed a signif-
icant difference between the IPD and SDS groups (P= .005) at 24mo. Intragroup
comparison showed significant improvement from baseline to 12 and 24 mo for
each treatment group (∗P < .001).
difference of –1% with a confidence interval of –10 to +7; P =
.005).
Improvement in ZCQ physical function, defined as a decrease
of ≥0.5 compared to baseline, was achieved by 54.2% of the
patients of the IPD group and 60.3% of the patients in the SDS
group at 24 mo.
ZCQ symptom severity improved significantly in both groups
from baseline to 12 mo (IPD: –31.2± 26.9%, P< .001 and SDS
–36.4± 24.5%, P< 0.001) and to 24 mo (IPD: –40.3± 21.9%,
P < .001 and SDS –32.8 ± 23.9%, P < .001; Table 3).
In both treatment groups, VAS pain scores for leg,
buttock/groin, and back pain showed that pain decreased
from baseline to 24 mo. No significant differences were observed
between the IPD and SDS groups for VAS leg, buttock/groin, or
VAS back pain scores. SF-36 v2 physical and mental aggregated
scores improved significantly for both treatment groups over
TABLE 4. VAS Leg and Back at Baseline and 12- and 24-mo
Follow-up
Baseline 12 mo 24mo
Mean (SD)
Leg pain
IPD 7.93 (1.31) 3.11 (2.74) 2.17 (2.49)
SDS 8.04 (1.32) 2.68 (2.60) 2.66 (2.59)
Back pain
IPD 4.00 (2.33) 3.15 (2.59) 2.17 (2.02)
SDS 4.38 (1.97) 2.89 (2.30) 3.05 (2.43)
Abbreviations: SDS, standalone decompressive surgery; IPD, interspinous process
device.
time (significant: P = .045 back pain, P = .01 leg pain; not
significant: buttock/groin pain, P = .144; Table 4).
Twenty-four months after the procedure, more than 59.7%
of patients implanted with an IPD walked fluently vs 41.6% of
the patients at baseline. In the SDS group, 61.3% of patients
were judged by their investigator to walk fluently, vs 37.3% at
baseline. Statistically significant improvement in walking distance
was observed for both groups at 24 mo after procedure (P< .001;
Table 5 and Figure 3).
Adverse Events and Additional Surgical Interventions
Seventy-four SAEs were recorded at up to 24 mo of follow-up,
39 SAE in the IPD group, and 35 SAE in the SDS group. The
number of patients experiencing at least 1 SAE was 26 (33.8%)
in the IPD group and 25 (33.3%) in the SDS group.
After 24 mo of follow-up, an additional surgical intervention
at index level was performed 21 times: 14 times in the IPD
group and 8 times in the SDS group (Table 6; Figure 4). Only
in 2 patients was a complication (spinous process fracture) the
reason for a revision in the IPD group. In 12 instances, however,
“lack of success” of the initial procedure (IPD implantation),
ie, early recurrence or unsatisfying relief of NIC symptoms, was
responsible for additional surgery in the index segment. In the
SDS group, 4 “typical” early complications (eg, hematoma or
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TABLE 5. Walking Distance at Baseline and 12- and 24-mo Follow-up
Baseline 12 mo 24mo
0-100m >1000m 0-100m >1000m 0-100m >1000m
IPD 29.9% 11.7% 5.2% 53.2% 3.9% 54.5%
SDS 37.3% 12.0% 4.0% 65.3% 6.7% 57.3%
Abbreviations: SDS, standalone decompressive surgery; IPD, interspinous process device.
FIGURE 3. Development of walking distances in A, the SDS group and B, the
IPD group was very similar following the respective intervention. Shorter walking
distances decreased, while walking distance >1000 m increased.
infections) were the reason for revision, and in 4 patients,
symptoms attributed to instability.
DISCUSSION
Our study results indicate that standalone IPDs are as effective
as standard decompression in patients with neurogenic claudi-
cation due to lumbar stenosis that is relieved by flexion. Although
treatment with an IPD was not noninferior to SDS treatment
at 12 mo, the prespecified primary endpoint, it was noninferior
at 24 mo. These results are in line with 3 recently published
randomized clinical trials.4-6
Our primary outcome and most of the secondary outcomes
are similar to the outcomes presented by Moojen,4 Strömquist,5
and Lønne,6 despite the fact that different implants were used.
Therefore, the sum of these findings represents level 1a evidence.
Without doubt, the key to this lies in the very strict indication
(classical NIC relieved by flexion in lumbar stenosis without
instability), which was applied in all studies alike. This also
demonstrates that correct and strict indication for a given
spinal disorder prevails over technical or biomechanical nuances
with regard to outcome. It also explains the contradicting
results seen in the vast majority of over 200 publications on
IPDs, reporting mostly uncontrolled data from heterogeneous
indications.9-11
Thus, IPDs may be regarded as a less invasive alternative
to open decompression in patients with NIC avoiding typical
surgical complications such as leaks or epidural hematomas.12
The results of all 4 studies point in this direction and do not raise
safety concerns with respect to the implants used.
However, the very high reoperation rate for IPD cohorts
remains themost problematic issue, with reoperation rates of 29%
after 12 mo and 26% after 24 mo being reported, compared to
6% and 8% in the control groups, respectively.4-6 A similarly high
reoperation rate has also been reported in a terminated study.12,13
The reoperations in the IPD cohorts in these studies were mostly
due to “lack of success” and were not revisions for obvious compli-
cations, as mostly seen in the decompression groups. We made a
similar observation in our investigational cohort (see Figure 4).
In the current study, the reoperation rate after 24 mo was 18.2%
in the IPD group, which is lower than in the other studies, while
the revision rate in the control group compares well with other
reliable data.14
This discrepancy constitutes a dilemma with regard to
clinical consequences and conclusions. The results of Moojen,4
Strömqvist,5 and Lønne6 lead us to conclude that the benefits of
IPDs are outweighed by the high revision rate. Moojen4 argues
that patients needing revisions fare worse than those who do not.
They deduce this from the results of Radcliff et al14 in a 4-yr
post hoc subgroup analysis of the original data of the SPORTS
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revision (d) Reason for revision Type of revision
1IPD 54 Persistent NIC Decompression and fusion 1SDS 1 Postop L5 palsy Revision
2IPD 112 Persistent NIC Decompression 2SDS 4 Epidural hematoma Revision
3IPD 145 Recurrent NIC Decompression 3SDS 8 Infection Revision




5IPD 254 Recurrent NIC Decompression 5SDS 401 Recurrent NIC Extended decompression
6IPD 348 Recurrent NIC Decompression and fusion 6SDS 609 New sciatica/
herniated disc
Decompression











10IPD 473 Recurrent NIC Decompression
11IPD 490 Recurrent NIC Decompression and fusion
12IPD 519 Persistent NIC Decompression
13IPD 644 Recurrent NIC Decompression
14IPD 707 Recurrent NIC Decompression
Abbreviations: SDS, standalone decompressive surgery; IPD, interspinous process device; NIC, neurogenic intermittent claudication.
trial (Weinstein et al).15 The outcome of the 13% of patients
needing repeat surgery after standard decompression was inferior
to the rest. This may also be the case after revision of an IPD,
but this is a mere extrapolation. Furthermore, the results from
Strömqvist are in contradiction to this, showing similar outcomes
for reoperated patients in the IPD group and after primary
decompression.5
Lønne et al6 describe 2 serious complications in the cohort of
patients receiving standard decompression, ie, 2 persisting cauda
syndromes.
Our study shows a somewhat more acceptable rate of reoper-
ation at the index segment of the IPD group compared to SDS.
Moreover, the percutaneous implantation technique offers a clear
advantage over open decompression (and the open implantation
technique of the other 2 devices) with respect to surgical time and
blood loss. The former would at least partially outweigh the direct
costs for the implant by substantially saving operating room time.
The IPD can also be implanted under local anesthesia as day care
surgery, which reduces associated costs. On the other hand, this
again might be foiled by the increase in costs due to the higher
rate of revision surgeries. As neither direct nor indirect costs were
measured in this study, that remains speculative.
The reasons for this discrepancy in revision rates might include
the following. Although we believe that technique and/or implant
is less important than indication, at least 1 worrisome aspect
with the choice of IPD in the FELIX trial remains.4 This
implant (Coflex, Paradigm Spine LLC, New York, New York)
was designed, marketed, and tested as a soft stabilization device
to be used in addition to open decompression.2 Its effectiveness
as a standalone device for this indication must be questioned.
This argument is certainly not true for the choice of implant in
Strömqvist’s5 and Lønne’s6 studies (X-Stop, Medtronic, Dublin,
Ireland).
However, a further confounder may have been introduced in
both studies due to a center effect, and Strömqvist acknowledges
this in his discussion.5 The trial was conducted in only 3 centers in
Sweden, and the high reoperation rate was mainly due to 1 center
alone. Thus, Strömqvist’s conclusion was more balanced than the
Dutch group’s, which completely rejected the use of IPDs on the
basis of their results.5
We believe that this indicates the most important problem,
which is a lack of equipoise. It is quite obvious that at the time
the trials were conducted, most surgeons had a clear, predefined
negative opinion on IPDs in general, due to officially and unoffi-
cially reported high reoperation rates (ie, Lønne, Verhoof ).6,9 It
was, therefore, an already common view that IPDs are an unsuc-
cessful device. This clearly introduces a bias when evaluating a
success or the lack thereof. Even though the evaluations in the
Dutch trial were done by a blinded research nurse, the indication
for revision lies in the hands of the surgeons.
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FIGURE4. Time to secondary surgical intervention at index level in both study groups after 24 mo. Fourteen patients
in the IPD group (18%) and 8 in the SDS group (9%) needed revision surgery in the index segment, the former in
a more delayed fashion and the latter rather early in the postoperative course. A lack of success, ie, persisting/recurring
symptoms, was given as the reason for revision in 12 cases in the IPD group. Four out of 8 patients in the SDS group
were revised early for typical operative complications. IPD = IPD group, SDS = SDS group.
Apart from this bias, we acknowledge that there may also be a
biomechanical reason for the earlier relapse of symptoms or “lack
of success” following IPD implantation. Taking into account
the radiological data, it becomes obvious that the gain in cross-
sectional area of the spinal canal is less with IPD than with open
decompression. This may be one of many factors for the shorter
“half-life” of these devices. No correlation of radiological and
clinical parameters could be shown in line with Moojen’s recent
publication.4
Due to the above arguments and in the light of our own results,
we would carefully advocate a more balanced view on standalone
IPD implantation for the treatment of DLSS with NIC. Progress
in clinical science only occurs in small steps. A complete rejection
of an innovation because of nonsuperiority would stall this process
for almost all technological evolutions. We value and share a
very critical attitude toward costly and/or ineffective innova-
tions. However, weighing the evidence available, we see a possible
indication in a small subset of patients, ie, those with comor-
bidities and/or anticoagulation.
CONCLUSION
This study confirms 3 recent prior randomized controlled trials
in showing that IPDs are as effective as standard decompression
in relieving symptoms of NIC due to lumbar stenosis in a highly
selected subset of patients. It also confirms that this occurs at the
price of a significantly higher reoperation rate. Percutaneous IPDs
may still have a very narrow window of indication in patients with
typical NIC due to lumbar stenosis and cardiac comorbidities
and/or anticoagulation, because surgery is shorter, safer, and less
invasive.
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COMMENT
T his multi-center, randomized, prospective trial compared percuta-neous interspinous process device (IPD) placement to standalone
decompressive surgery (SDS) for degenerative lumbar stenosis. Designed
as a non-inferiority trial, this investigation found that IPD was not less
effective than SDS. Although this randomized study should be viewed as
higher level evidence in regards to the effectiveness of IPD, there are a
few points that should be highlighted. Based on the inclusion/exclusion
criteria, only a subset of patients with lumbar stenosis would qualify.
More problematic is that reoperation rates were much higher in this
study, which has been observed in other studies of IPD. Increased reoper-
ation rates are a burden to the patient and likely contribute to increased
costs. This begs the question of why an IPD should be implanted instead
of performing a traditional SDS.
Paul Park
Ann Arbor, Michigan
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